X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Press Statements

Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Content Team by Content Team
24th January 2019
in Press Statements, Research & Development
Astellas and KM Biologics Expiration of Distribution Agreement for Human Vaccines, etc. and Blood Plasma Products

Astellas Pharma Inc and KM Biologics Co., Ltd. announced that the agreement for the distribution by Astellas of human vaccines, etc. and blood plasma products , which KM Biologics manufactures and sells in Japan, will expire on July 31, 2019. In accordance with the expiration of the agreement, distribution of the products will be transferred as follows.

In terms of human vaccines, etc., Meiji Seika Pharma Co., Ltd. (“Meiji Seika Pharma”), which is an affiliate of Meiji Holdings Co., Ltd. same as KM Biologics, will distribute them as soon as, after April 2019, Astellas’ inventory of those products runs out, based on the distribution agreement concluded by KM Biologics with Meiji Seika Pharma. Meanwhile, Meiji Seika Pharma will provide and collect information on the products from medical institutions from April 1, 2019.

In terms of blood plasma products, Japan Blood Products Organization (“JB”) will distribute them, and provide and collect information on those products from medical institutions from August 1, 2019, based on the distribution agreement concluded by KM Biologics with JB.

Astellas and KM Biologics will work closely with Meiji Seika Pharma and JB to ensure a smooth transfer of the distribution of the products to continue delivering them to patients stably.

List of the major products
“Human vaccines, etc.”
Influenza HA Vaccine “KMB”, Quattrovac, ENCEVAC, Bimmugen,
Aimmugen, Inactivated Tissue Culture Rabies Vaccine,
and Freeze-dried Mamushi Antivenom “KMB”, etc.

“Blood plasma fraction Formulations”
BOLHEAL®, Confact® F, Novact® M, etc.

Sales of the Products by Astellas (Fiscal year ended March 31, 2018)
Approximately 24 billion yen (gross sales basis)

About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people
around the world through the provision of innovative and reliable pharmaceutical products. For more
information, please visit our website at https://www.astellas.com/en

About KM Biologics
KM Biologics Co., Ltd. is a Kumamoto (Japan) based company that supplies high-quality biological
products and services to create a healthy future for people all around the world.
Please visit our website for more information: http://www.kmbiologics.com/en/

Previous Post

TrakCel and Quick partner to provide Digital Supply Chain IT solution for Cell and Gene Therapies

Next Post

TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

Related Posts

Avadel Pharmaceuticals Receives
Drug Development

Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

9th June 2025
Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
ACHEMA
Middle East and South Asia

ACHEMA Middle East to Debut in Riyadh in 2026 Trade Show

9th May 2025
Next Post
TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

TC BioPharm creates allogeneic cell banks for CAR T cancer therapy products

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In